uniQure N.V. (QURE)

NMS – Real Time Price. Currency in USD

29.10

+1.46 (5.28%)

At close: May 12, 2026, 4:00 PM EDT

29.26

+0.16 (0.55%)

Pre-market: May 13, 2026, 4:00 AM EDT

12.05.2026

UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play

UniQure is upgraded from Hold to Buy, driven by near-term UK approval prospects for AMT-130 and a robust cash runway to 2029. Despite FDA requiring a new Phase 3 trial for AMT-130 in Huntington's, a UK submission is imminent, positioning QURE for a major catalyst. QURE's pipeline, including AMT-260 for epilepsy and AMT-191 for Fabry, offers additional upside, though AMT-162 was discontinued.

05.05.2026

uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript

05.05.2026

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure (QURE) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.82 per share a year ago.

05.05.2026

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~

30.04.2026

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~

28.04.2026

uniQure to Announce First Quarter 2026 Financial Results

~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass.

13.04.2026

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
QURE	Mizuho	Outperform	undefined >> $35	March 11th 2026
QURE	RBC Capital Mkts	Outperform	undefined >> $35	March 9th 2026
QURE	Wells Fargo	Overweight	undefined >> $60	March 9th 2026
QURE	Wells Fargo	Equal Weight	undefined >> $15	March 3rd 2026
QURE	Mizuho	Neutral	undefined >> $12	March 3rd 2026
QURE	RBC Capital Mkts	Sector Perform	undefined >> $11	March 2nd 2026
QURE	Cantor Fitzgerald	Neutral	undefined >> $9	March 2nd 2026
QURE	Wolfe Research	Peer Perform	undefined >> undefined	February 24th 2026

Press releases

05.05.2026

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~

30.04.2026

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~

13.04.2026

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit.

13.04.2026

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - April 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) and certain of its officers.

uniQure N.V. (QURE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

uniQure N.V. (QURE)

UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play

uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

uniQure to Announce First Quarter 2026 Financial Results

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

Videos

No Data

Upgrades / Downgrades

Press releases

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play

uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

uniQure to Announce First Quarter 2026 Financial Results

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

Videos

No Data

Upgrades / Downgrades

Press releases

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

Search stocks

uniQure N.V. (QURE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

uniQure N.V. (QURE)

UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play

uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

uniQure to Announce First Quarter 2026 Financial Results

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

Videos

No Data

Upgrades / Downgrades

Press releases

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play

uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

uniQure to Announce First Quarter 2026 Financial Results

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

Videos

No Data

Upgrades / Downgrades

Press releases

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm